MTIP
CLLS

Magee Thomson Investment Partners’s Cellectis CLLS Stock Holding History

Magee Thomson Investment Partners’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$1K Buy
+26
New +$546 ﹤0.01% 37

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Magee Thomson Investment Partners's CLLS Position: Q1 2017 in Review

Magee Thomson Investment Partners opened a new position in Cellectis (CLLS) in Q1 2017: 26 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #37 among its holdings.

40 funds tracked by Wall St. Rank hold CLLS as of Q1 2017.

  • Magee Thomson Investment Partners held 26 shares of Cellectis worth $1K as of Q1 2017.
  • Cellectis was a new Magee Thomson Investment Partners position in Q1 2017.
  • Cellectis made up ﹤0.01% of Magee Thomson Investment Partners's portfolio in Q1 2017, its #37 holding.
  • 40 funds tracked by Wall St. Rank held Cellectis as of Q1 2017.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2017, filed 21 Apr 2017.